Ingredient Guide
Fadogia Agrestis: Benefits, Dosage, and What the Research Says
A West African herb with growing supplement popularity and very thin human evidence
Written by Jessica Medson
Fadogia agrestis is a small West African shrub whose stem extract has been used in traditional medicine for centuries to support male vitality and energy. Preclinical rat studies suggest the aqueous stem extract may raise serum testosterone levels and improve sexual behavior parameters in a dose-dependent manner, but no human clinical trials have established these effects in people. Critically, the same rodent research that identified potential testosterone-supporting activity also documented dose-dependent testicular toxicity at higher doses - a safety signal that remains entirely unresolved due to a complete absence of human long-term safety data.
What Is Fadogia Agrestis?
Fadogia agrestis (Schweinf. Ex Hiern) is a small shrub belonging to the Rubiaceae family - the same botanical family as coffee and quinine. It grows natively across the Guinea-Sudan Savanna belt of West Africa, with the strongest tradition of use in northern Nigeria, where it is known locally as bakin gagai in the Hausa language, and in Burkina Faso, where ethnobotanical surveys have recorded its use for fever, rheumatism, and pain management.9
Herbalists in the region have historically prepared decoctions from the dried stem, primarily to support male sexual vitality and energy. Contemporary supplement interest surged largely on the basis of a single 2005 animal study1 and enthusiastic word-of-mouth promotion in fitness communities. Online discourse - amplified substantially by well-known podcast figures - outpaced the scientific literature by a wide margin, and this ingredient remains one of the most hyped, yet least evidenced, testosterone-adjacent supplements currently on the market.
Botanical profile at a glance
- Family: Rubiaceae
- Common names: Fadogia, bakin gagai (Hausa); also classified as Vangueria agrestis in some taxonomic systems
- Part used: Stem (aqueous extract in all major published studies)
- Native range: Northern Nigeria, Burkina Faso, and the Guinea-Sudan Savanna zone of West Africa
- Key phytochemicals identified: Alkaloids, steroidal saponins, monoterpene glycosides,4 ursane-type triterpenoid glycosides, benzophenone glycosides,5 novel monoterpene rhamnosides,8 and anthraquinones1
How Does It Work? Proposed Mechanisms
Researchers have proposed several mechanisms by which Fadogia agrestis extracts may exert biological effects. All of these remain theoretical in humans because no mechanism studies have been performed in clinical populations.
Testosterone pathway: LH stimulation hypothesis
The leading hypothesis is that steroidal saponins in the stem extract stimulate the pituitary gland to release luteinizing hormone (LH). LH then signals Leydig cells in the testes to increase testosterone biosynthesis through the hypothalamic-pituitary-gonadal (HPG) axis. In the 2005 rat study,1 serum testosterone concentrations rose in a dose-dependent manner across all three dosing groups, which is consistent with this model - though LH itself was not directly measured. The saponin fraction is most often proposed as the primary driver.
Nitric oxide and cGMP pathway
A 2023 rat study7 found that aqueous Fadogia agrestis extract restored nitric oxide (NO) and cyclic GMP (cGMP) levels in penile and testicular tissues of male rats with paroxetine-induced erectile dysfunction, while simultaneously reducing phosphodiesterase-5 (PDE5) activity - the same enzyme targeted by prescription medications like sildenafil. The researchers attributed this to antioxidant-mediated restoration of the vascular signaling cascade. No human data support this pathway.
Phytochemical complexity and a product quality concern
Multiple phytochemical investigations have confirmed that the plant contains a structurally complex mixture of bioactive compounds, including monoterpene glycosides,4 three previously undescribed monoterpene rhamnosides named vangagrestosides A-C,8 and glycosides with demonstrable activity against Trypanosoma brucei in laboratory assays.5 A major practical concern for supplement consumers: an analytical survey using UHPLC-PDA-MS found that among 17 commercial Fadogia agrestis products, five contained no detectable phenolic compounds whatsoever, while those that did contained only 0.3-2.7 mg of phenolics per daily dose.6 This substantial product variability makes even theoretical conclusions about what consumers are actually ingesting difficult to draw.
Testosterone Support: Animal Evidence and Its Limits
The most frequently cited reason people take Fadogia agrestis is to help maintain healthy testosterone levels within the normal range. This claim rests entirely on preclinical animal data (Tier C evidence). No human clinical trial has been published as of the date of this article.
What the research shows
In the primary published study by Yakubu, Akanji, and Oladiji (2005),1 male albino rats received 18, 50, or 100 mg/kg of aqueous Fadogia agrestis stem extract orally once daily. Serum testosterone concentrations were measured on days 1, 3, and 5. All three dose groups showed statistically significant, dose-dependent increases in serum testosterone across the observation period. Phytochemical screening confirmed alkaloids and saponins as the primary constituents of the extract, with anthraquinones and flavonoids also weakly present.
The investigators proposed that steroidal saponins may have driven endogenous testosterone production by stimulating LH release - a plausible mechanism given saponin pharmacology in other plant species, but one that remains unconfirmed.
Critical limitations every reader should understand
- The study lasted only five days and used a small number of animals per group - it was not designed or powered to establish human efficacy.
- Rat endocrine physiology differs substantially from human hormonal regulation; many compounds that raise testosterone in rodents produce no measurable effect in clinical trials.
- The same research group subsequently found dose-dependent testicular damage in a 28-day rat study at the 50 and 100 mg/kg doses used in the 2005 experiment,2 raising the question of whether any testosterone-supporting effect in animals comes at an unacceptable cost to tissue health - and whether the same tradeoff would exist in humans.
- No human dose-finding, pharmacokinetic, or efficacy trial has been completed or published in any peer-reviewed journal.
Evidence classification: Tier C - animal data only. Human evidence has not been established. This ingredient cannot be characterized as a proven testosterone booster in humans.
Sexual Function and Aphrodisiac Activity
Traditional West African use of Fadogia agrestis has long emphasized male sexual vitality, and this ethnobotanical context motivated the first modern laboratory investigations.9
What the research shows
The 2005 rat study1 recorded improvements in multiple validated aphrodisiac behavioral parameters: significantly increased mount frequency, increased intromission frequency, prolonged ejaculatory latency, and reduced mount and intromission latency - all at every dose tested. The authors concluded that elevated serum testosterone was the most likely driver of these behavioral changes.
A 2023 mechanistic study7 using a rat model of antidepressant-induced sexual dysfunction found that aqueous Fadogia agrestis extract restored key biochemical markers of erectile function: penile and testicular nitric oxide, cGMP, catalase, superoxide dismutase, total sulfhydryl groups, and glutathione were all significantly elevated toward control values, while PDE5, arginase, acetylcholinesterase, and markers of oxidative damage were reduced. The researchers described the magnitude of effect as comparable to the sildenafil reference control and recommended clinical evaluation in humans. No such trials have been reported.
There are no published human studies evaluating Fadogia agrestis for libido, sexual behavior, or erectile function. Any benefit in this area for human consumers is speculative, based solely on animal model data.
Evidence classification: Tier C - animal data only. Human evidence has not been established.
Safety, Side Effects, and Interactions
This section addresses the most clinically important aspect of the Fadogia agrestis evidence base. The animal research that generated hypotheses about potential benefits also documented meaningful, dose-dependent safety signals. None of these has been characterized in humans, and no long-term human safety study exists.
Testicular toxicity signal (animal data - Tier C)
In a 28-day rat study by Yakubu et al. (2008),2 aqueous Fadogia agrestis extract administered at 18, 50, and 100 mg/kg produced significant alterations in testicular biochemical markers across all dose groups: testicular cholesterol, sialic acid, and glycogen increased while alkaline phosphatase activity and total protein concentration declined. The investigators described these findings as "indications of adverse effects on male rat testicular function." Histopathological examination revealed destruction of spermatic cells and seminiferous tubules that was mild and reversible at 18 mg/kg but irreversible at 50 and 100 mg/kg. Commercial supplement doses, when scaled allometrically, may correspond to dose ranges within the problematic zone observed in these animals - though this comparison is uncertain in the absence of human pharmacokinetic data.
Liver and kidney stress markers (animal data - Tier C)
A 2009 toxicology study3 found that 28-day administration significantly disrupted liver and kidney enzyme activity and elevated serum malondialdehyde - a validated marker of oxidative stress and lipid peroxidation in cell membranes - at all three dose levels tested, including the lowest. The authors proposed that saponins and other constituents disrupt hepatocyte and nephron cell membranes through oxidative damage. No mortality or gross organ damage was recorded, but the biochemical profile indicated sub-clinical organ stress across the full dose range.
No human safety data
As of the date of this publication, no controlled human safety study of Fadogia agrestis has been published. The ingredient does not carry a GRAS (generally recognized as safe) designation. Case reports exist of severe adverse events - including cardiovascular complications - in individuals using multi-ingredient supplement stacks containing Fadogia agrestis, though causality cannot be assigned from those reports given the presence of other co-ingredients.
Contraindications and special populations
- Pregnancy and breastfeeding: Avoid entirely. No safety data exist, and theoretical hormonal and organ-toxicity activity presents unacceptable risk.
- Hormone-sensitive conditions: Individuals with prostate cancer, testicular cancer, benign prostatic hyperplasia, or other hormone-sensitive conditions should not use this supplement without direct physician supervision.
- Kidney or liver disease: Animal data showing hepatic and renal enzyme disruption at every dose level3 make use inadvisable without medical oversight.
- Children and adolescents: No data; avoid.
- Drug interactions: Theoretical interactions with testosterone replacement therapy, anabolic steroids, phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil), and anticoagulants have not been studied and cannot be ruled out.
Product quality risk
An analytical survey of 17 commercial Fadogia agrestis products found that 5 contained no detectable active phenolic compounds at all,6 and content among those that did varied from 0.3 to 2.7 mg per daily serving. Choose products that provide third-party testing certificates of analysis from accredited laboratories (NSF International, Informed Sport, or USP are recognized benchmarks).
Fadogia Agrestis Dosage Reference
No human clinical dose-finding study for Fadogia agrestis has been published. The entries below reflect doses used in rat studies (which cannot be directly extrapolated to humans) alongside typical commercial supplement doses. This table is provided for informational context only and does not constitute a dosage recommendation for any person.
| Goal | Typical Dose | Timing | Notes |
|---|---|---|---|
| Dose used in primary animal testosterone study (rat model only) | 18-100 mg/kg body weight | Once daily; testosterone evaluated at days 1, 3, and 5 | Rat doses. Direct extrapolation to human dosing is not scientifically valid. The lowest dose (18 mg/kg) was the only level showing reversible, rather than irreversible, testicular changes in follow-up safety studies. |
| Dose range associated with irreversible testicular damage in rats | 50-100 mg/kg body weight | Once daily for 28 days | This range produced irreversible seminiferous tubule destruction in the 28-day toxicology study. Noted here as a safety reference, not a target dose. |
| Typical commercial supplement dose (not validated by human trials) | 425-600 mg per day | Typically once daily, often taken with a meal | Manufacturer-derived from animal data extrapolation. Not validated by human clinical trial. Product quality varies significantly; five of 17 products in one analytical study contained no detectable active compounds. |
Do not use these figures as a personal dosing guide. No dose of Fadogia agrestis has been proven safe or effective in humans. Consult a qualified healthcare provider before use, particularly if you have any underlying health conditions, take medications, or are considering long-term supplementation.
Fadogia Agrestis: What the Evidence Shows at a Glance
All evidence below comes from animal or in vitro models. Human clinical evidence has not been established for any of these outcomes.
| Outcome | Animal or Lab Finding | Human Clinical Evidence | Evidence Grade |
|---|---|---|---|
| Serum testosterone | Significant dose-dependent increase in male rats at all doses after 5 days of oral dosing | None - no human trials published | Tier C (animal only) |
| Sexual behavior / libido | Improved mount frequency, reduced mount latency, and increased intromission frequency in rats | None | Tier C (animal only) |
| Erectile function (NO/cGMP pathway) | Restored nitric oxide, cGMP, and antioxidant enzymes in penile/testicular tissue of paroxetine-treated rats, comparable to sildenafil reference | None | Tier C (animal only) |
| Testicular health | Dose-dependent adverse biochemical changes; mild and reversible at lowest dose, irreversible seminiferous tubule damage at 50-100 mg/kg | None | Tier C (safety concern - animal) |
| Liver and kidney markers | Elevated oxidative stress markers and disrupted enzyme activity at all doses in 28-day rat study | None | Tier C (safety concern - animal) |
| Antimalarial activity | IC50 4-10 mcg/mL against chloroquine-resistant Plasmodium falciparum in vitro | None | Tier C (in vitro) |
Tier A = human RCT or meta-analysis. Tier B = human observational study. Tier C = animal or cell data only; human evidence not established.
Frequently Asked Questions
What is Fadogia Agrestis good for?
Based on traditional West African use and preclinical animal studies, Fadogia agrestis is taken to help maintain healthy testosterone levels and support male sexual vitality. However, every piece of published evidence comes from rat studies - no human clinical trial has confirmed any benefit. The evidence base is very thin, and documented animal-model safety signals add meaningful uncertainty for human users.
Does Fadogia Agrestis actually raise testosterone in humans?
No human trial has tested this. A 2005 rat study found dose-dependent increases in serum testosterone over five days, which is where the claim originates. Rodent testosterone responses do not reliably translate to human outcomes - many herbal compounds that raise testosterone in rats show no effect in clinical trials. Fadogia agrestis cannot be characterized as a proven testosterone booster in people.
How much Fadogia Agrestis should I take?
No human dose-finding study exists to answer this. Animal studies used 18-100 mg/kg in rats; commercial supplements typically provide 425-600 mg per day, a dose derived from animal data extrapolation rather than human pharmacology. No dose is proven safe or effective in people. Consult a healthcare provider before use and start at the lowest dose on any product label.
What are the side effects of Fadogia Agrestis?
No controlled human study has documented side effects. Animal studies raise serious concerns: dose-dependent testicular damage (irreversible at higher doses), liver enzyme disruption, and kidney oxidative stress markers were observed in rats at all doses tested. Case reports exist of severe adverse events in people using multi-ingredient stacks containing Fadogia agrestis, though individual causality is unestablished.
Is Fadogia Agrestis safe?
Safety in humans has not been established. Rat studies documented dose-dependent testicular damage, hepatic enzyme disruption, and kidney oxidative stress at all doses tested over 28 days - including the lowest dose. No long-term human safety data exist. People with liver or kidney disease, hormone-sensitive conditions, or those who are pregnant should avoid it entirely.
Can women take Fadogia Agrestis?
Women should avoid Fadogia agrestis. It has been studied exclusively in male animal models focused on testosterone-related effects, and no safety data exist for women. Pregnant and breastfeeding women should not use it under any circumstances due to theoretical hormonal activity and a complete absence of reproductive safety data.
How long does Fadogia Agrestis take to work?
No human pharmacokinetic or efficacy data exist to answer this. In the five-day rat study, testosterone increases were detectable by day 1 and grew through day 5. Whether any comparable timeline or effect would apply in humans is unknown. This question cannot be answered honestly with the current evidence.
Does Fadogia Agrestis damage the kidneys or liver?
Animal studies raise concern. A 28-day rat study found that Fadogia agrestis extract disrupted liver and kidney enzyme activity and elevated malondialdehyde - a marker of oxidative cell membrane damage - at every dose level tested, including the lowest. No human kidney or liver safety study has been conducted. Individuals with existing organ impairment should not use this ingredient.
What is Fadogia Agrestis usually stacked with?
It is frequently marketed alongside Tongkat Ali (Eurycoma longifolia) and zinc as part of a 'testosterone support stack.' Tongkat Ali has a modestly stronger human evidence base - including several small RCTs - than Fadogia agrestis, which has none. No study has evaluated the safety or efficacy of the combination, and stacking untested compounds multiplies rather than reduces uncertainty.
Is Fadogia Agrestis the same as Tongkat Ali?
No - they are completely different plants. Tongkat Ali (Eurycoma longifolia) is a Malaysian tree in the Simaroubaceae family with several published human clinical trials showing modest testosterone-supporting effects. Fadogia agrestis is a West African shrub with zero published human trials. They are sometimes combined in supplements but represent substantially different evidence bases and risk profiles.
Shop Fadogia Agrestis
HealthFare Fadogia Agrestis supplements
Scientific References
- 1.Yakubu MT, Akanji MA, Oladiji AT Aphrodisiac potentials of the aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male albino rats. Asian Journal of Andrology. 2005. PubMed: 16281088Preclinical (animal / cell)
- 2.Yakubu MT, Akanji MA, Oladiji AT Effects of oral administration of aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem on some testicular function indices of male rats. Journal of Ethnopharmacology. 2008. PubMed: 18023305Preclinical (animal / cell)
- 3.Yakubu MT, Oladiji AT, Akanji MA Mode of cellular toxicity of aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male rat liver and kidney. Human and Experimental Toxicology. 2009. PubMed: 19755438Preclinical (animal / cell)
- 4.Anero R, Diaz-Lanza A, Ollivier E, Baghdikian B, Balansard G, Bernabe M Monoterpene glycosides isolated from Fadogia agrestis. Phytochemistry. 2008. PubMed: 17988698Preclinical (animal / cell)
- 5.Osman AG, Ali Z, Fantoukh O, Raman V, Kamdem RST, Khan I Glycosides of ursane-type triterpenoid, benzophenone, and iridoid from Vangueria agrestis (Fadogia agrestis) and their anti-infective activities. Natural Products Research. 2020. PubMed: 30325205Preclinical (animal / cell)
- 6.Avula B, Bae JY, Raman V, Fantoukh OI, Wang YH, Osman AG, Wang M, Ali Z, Khan IA Quantification of Phenolic Compounds from Fadogia agrestis and Dietary Supplements using UHPLC-PDA-MS. Planta Medica. 2019. PubMed: 30170324Preclinical (animal / cell)
- 7.Ogunro OB, Yakubu MT Fadogia agrestis (Schweinf. Ex Hiern) Stem Extract Restores Selected Biomolecules of Erectile Dysfunction in the Testicular and Penile Tissues of Paroxetine-Treated Wistar Rats. Reproductive Sciences. 2023. PubMed: 35969364Preclinical (animal / cell)
- 8.Osman AG, Fantoukh O, Ali Z, Raman V, Ibrahim MA, Khan IA Three undescribed monoterpene rhamnosides from the aerial parts of Vangueria agrestis. Natural Products Research. 2021. PubMed: 32093520Preclinical (animal / cell)
- 9.Sanon S, Ollivier E, Azas N, Mahiou V, Gasquet M, Ouattara CT, Nebie I, Traore AS, Esposito F, Balansard G, Timon-David P, Fumoux F Ethnobotanical survey and in vitro antiplasmodial activity of plants used in traditional medicine in Burkina Faso. Journal of Ethnopharmacology. 2003. PubMed: 12738078Preclinical (animal / cell)